Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658437 | 0.86 | MTNR1A (0.65) | MTNR1ATP53ACLYMALT1HDAC1 | |
| SCHEMBL15045823 | 0.76 | TP53 (0.60) | MTNR1ATP53MALT1 | |
| SCHEMBL9692800 | 0.75 | MALT1 (0.53) | MTNR1ATP53ACLYMALT1HDAC1 | |
| SCHEMBL9692869 | 0.75 | MALT1 (0.57) | MTNR1ATP53MALT1HDAC1SIGMAR1 | |
| SCHEMBL6554292 | 0.74 | SIGMAR1 (0.51) | TP53ACLYMALT1HDAC1HTR1A | |
| SCHEMBL27525681 | 0.74 | SIGMAR1 (0.51) | TP53ACLYMALT1HDAC1HTR1A | |
| SCHEMBL30098372 | 0.73 | TP53 (0.62) | TP53HDAC1MAOB | |
| SCHEMBL2247241 | 0.73 | SIGMAR1 (0.52) | TP53ACLYMALT1HDAC1HTR1A | |
| SCHEMBL8354157 | 0.73 | SIGMAR1 (0.52) | TP53ACLYMALT1HDAC1HTR1A | |
| SCHEMBL13572973 | 0.73 | SIGMAR1 (0.52) | TP53ACLYMALT1HDAC1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | MTNR1A 40/4885TP53 4493/4885ACLY 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.